Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

New Contract Win

12 Jun 2007 07:00

Marchpole Holdings PLC12 June 2007 MARCHPOLE HOLDINGS PLC Exclusive Jeans Partnership with Lee Cooper Marchpole Holdings plc, (LSE: MPH), the fast growing fashion brand managementgroup, is pleased to announce that its wholly-owned subsidiary Jean Charles deCastelbajac ("JCC") has signed a long term partnership agreement with Lee CooperInc. ('Lee Cooper'), the global denim brand. Under the terms of the agreement, which is for an initial period of five years,two new designer denim lines will be launched in partnership with Lee Cooper forthe Spring/Summer 2008 season. These will be the only premium denim linesoffered by Lee Cooper. JCC will receive royalties on all wholesale and retailsales. All marketing and development of this venture will be jointly funded. JCC will design the main line, branded "JC-DC". This exclusive collection formen and women, themed around contemporary British 60s rock icons, will targetthe younger end of the market, and initially will be distributed through 250 LeeCooper retail stores and JCC flagship stores worldwide. In total, Lee Cooper hassome 500 retail stores. Alongside the mainline collection JCC will design a high-end denim collection,JC de Castelbajac, with a couture finish and targeting existing JCC customers.This collection will be sold in JCC flagship stores worldwide and also top endLee Cooper stores. Michael Morris, Marchpole Executive Deputy Chairman commented: "We are delightedto sign this agreement with Lee Cooper, one of the world's original denimcompanies. The partnership is yet another step in broadening the customer baseof Jean Charles De Castelbajac, into the lucrative denim market. We believe thatthis partnership is a great cultural and strategic fit for both brands and welook forward to a long and successful relationship with Lee Cooper." - ends - For further information, please contact: Bell Pottinger Corporate & Financial 020 7861 3232David Rydell/Emma Kent/Amy Rajendran Marchpole Holdings plc 020 7908 7700Michael Morris, Executive ChairmanJohn Harrison, Finance Director Note to Editors: - Marchpole Holdings plc ("Marchpole") is an international brandmanagement group that designs, produces and sells clothing and accessories fornine globally recognised fashion labels. It operates in all of the world's mainmarkets - UK, mainland Europe, Middle East, Asia and the USA - Its respected brands include Boateng, Emmanuel Ungaro, Ungaro, JeanCharles de Castelbajac ("JCC"), Jean Charles de Castelbajac / Rossignol, JeanCharles de Castelbajac/Okaidi, Jean Charles de Castelbajac / New Era, JeanCharles de Castelbajac/Lee Cooper and Homebody - Marchpole is renowned for its integrated approach to brandmanagement, taking a brand from concept to design studio to the customerinterface. It is not a clothing manufacturer - The Group has grown considerably in the past four years, from alicensee with one core license (YSL menswear) - to today's internationalbusiness that manages its brands across a multitude of clothing lines andaccessories - Marchpole's acquisition (March 2006) of Moda America - the USlicensee for leading designer Emanuel Ungaro - provided further growthopportunities in the UK and America and strengthened the Company's relationshipwith Ungaro - The acquisition also enabled the Company to launch the Ungaro brand,already established by Marchpole in Europe and Asia, into the US, Canada andSouth America. The acquisition has also enabled the Company to re-launch JCCinto America. - In March 2007 Marchpole acquired 100% of Greenmark Limited, an importer and wholesaler of ladies shoes who currently supply in excess of 2.5 million pairs of shoes per annum. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSExercise of Options
23rd Jul 20187:00 amRNSNotice of Interim Results
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.